Dendritic-Tumor Fusion Cell-Based Cancer Vaccines
AbstractDendritic cells (DCs) are potent antigen-presenting cells (APCs) that play a critical role in the induction of antitumor immunity. Therefore, various strategies have been developed to deliver tumor-associated antigens (TAAs) to DCs as cancer vaccines. The fusion of DCs and whole tumor cells to generate DC-tumor fusion cells (DC-tumor FCs) is an alternative strategy to treat cancer patients. The cell fusion method allows DCs to be exposed to the broad array of TAAs originally expressed by whole tumor cells. DCs then process TAAs endogenously and present them through major histocompatibility complex (MHC) class I and II pathways in the context of costimulatory molecules, resulting in simultaneous activation of both CD4+ and CD8+ T cells. DC-tumor FCs require optimized enhanced immunogenicity of both DCs and whole tumor cells. In this context, an effective fusion strategy also needs to produce immunogenic DC-tumor FCs. We discuss the potential ability of DC-tumor FCs and the recent progress in improving clinical outcomes by DC-tumor FC-based cancer vaccines. View Full-Text
Share & Cite This Article
Koido, S. Dendritic-Tumor Fusion Cell-Based Cancer Vaccines. Int. J. Mol. Sci. 2016, 17, 828.
Koido S. Dendritic-Tumor Fusion Cell-Based Cancer Vaccines. International Journal of Molecular Sciences. 2016; 17(6):828.Chicago/Turabian Style
Koido, Shigeo. 2016. "Dendritic-Tumor Fusion Cell-Based Cancer Vaccines." Int. J. Mol. Sci. 17, no. 6: 828.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.